VKA therapy inhibits factors II, VII, IX, and X and causes a prolonged PT.

VKAs can prevent stroke or systemic embolization among patients with atrial fibrillation and can treat and prevent venous thromboembolism. The impact of VKAs on clotting is assessed via the International Normalized Ratio: INR = (PT patient/MNPT)^ISI. HORIBA offers a comprehensive range for monitoring of VKA therapy:

• Yumizen G PT Liq 4: the universal reagent, liquid & ready to use for semi-auto and full-auto systems.

Heparin is a commonly used medication in the treatment and prophylaxis of thromboembolic disorders effective for prevention and treatment of venous thrombosis and pulmonary embolism, for prevention of mural sural thrombosis after myocardial infarction and for treatment of patients with unstable angina.

• ACTICHROME Heparin Anti-Xa is a specific, easy to use and fully automated test. Dedicated calibration curves for greater accuracy of your unfractionated heparin and low molecular weight heparin measurement. It is the solution of choice for UFH, LMWH testing.